Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fluticasone Propionate

FDA-approved product (ointment, topical), marketed as Armonair Digihaler, Armonair Respiclick, Cutivate and 9 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Fluticasone Propionate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Allergic rhinitis
  • Asthma
  • Atopic eczema
  • Chronic bronchitis
  • Chronic obstructive pulmonary disease
  • Emphysema
  • Nasal Cavity Polyp
  • Nasal congestion
  • Nasal polyposis
  • Seasonal allergic rhinitis
  • Skin disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, potent (group iii); Corticosteroids; Glucocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fluticasone Propionate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fluticasone Propionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model

    NCT01134328 · start 2010-05

    Registered record
    Registry ID
    NCT01134328
    Conditions
    Allergic Conjunctivitis
    Interventions
    AC-150 Combo; AC-150A 0.1%; AC-150B 0.005%; Vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-05
    Completion
    2010-07
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Conjunctivitis
    InterventionAC-150 Combo; AC-150A 0.1%; AC-150B 0.005%; Vehicle
    PhasePhase 2
    Registry statusCompleted

  • Sub-Sensitivity to Long-Acting Bronchodilators (LABA)

    NCT01117116 · start 2010-03

    Registered record
    Registry ID
    NCT01117116
    Conditions
    Asthma
    Interventions
    fluticasone propionate and salmeterol; budesonide and formoterol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-03
    Completion
    2013-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    Interventionfluticasone propionate and salmeterol; budesonide and formoterol
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

    NCT01054885 · start 2009-10-19

    Registered record
    Registry ID
    NCT01054885
    Conditions
    Pulmonary Disease, Chronic Obstructive
    Interventions
    FF Inhalation Powder; FF/GW642444 Inhalation Powder; GW642444 Inhalation Powder; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-10-19
    Completion
    2011-02-08
    Enrolment
    1,226

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease, Chronic Obstructive
    InterventionFF Inhalation Powder; FF/GW642444 Inhalation Powder; GW642444 Inhalation Powder; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Usefulness of Exhaled Breath Condensate for Evaluation of Markers of Airway Inflammation in Children With Asthma

    NCT00961155 · start 2009-08

    Registered record
    Registry ID
    NCT00961155
    Conditions
    Asthma
    Interventions
    cyklezonid; montelukast sodium; placebo; formoterol 12 mcg twice daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2009-08
    Completion
    2014-06
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    Interventioncyklezonid; montelukast sodium; placebo; formoterol 12 mcg twice daily
    PhasePhase 2
    Registry statusUnknown

  • Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma

    NCT00980707 · start 2009-08

    Registered record
    Registry ID
    NCT00980707
    Conditions
    Allergic Asthma
    Interventions
    Inhaled corticosteroid (fluticasone)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-08
    Completion
    2010-11
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Asthma
    InterventionInhaled corticosteroid (fluticasone)
    PhasePhase 4
    Registry statusCompleted

  • A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis

    NCT00682643 · start 2008-06

    Registered record
    Registry ID
    NCT00682643
    Conditions
    Rhinitis, Allergic, Perennial
    Interventions
    fluticasone furoate nasal spray; vehicle placebo nasal spray
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-06
    Completion
    2011-02
    Enrolment
    550

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial
    Interventionfluticasone furoate nasal spray; vehicle placebo nasal spray
    PhasePhase 4
    Registry statusCompleted

  • Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation

    NCT00487032 · start 2008-05

    Registered record
    Registry ID
    NCT00487032
    Conditions
    Allergic Rhinitis; Tachyphylaxis; Rhinitis Medicamentosa
    Interventions
    Oxymetazoline 0.05% w/v; Fluticasone propionate 50 micrograms per actuation; Prazosin hydrochloride; Placebo to Prazosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-05
    Completion
    2009-05
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis; Tachyphylaxis; Rhinitis Medicamentosa
    InterventionOxymetazoline 0.05% w/v; Fluticasone propionate 50 micrograms per actuation; Prazosin hydrochloride; Placebo to Prazosin
    PhasePhase 4
    Registry statusCompleted

  • A Study Designed to Determine if the Drugs Albuterol (Salbutamol) and Fluticasone Have an Effect on the Pharmacokinetics of the Investigational Product Technosphere® Insulin Inhalation Powder in Healthy Volunteers

    NCT00674050 · start 2008-05

    Registered record
    Registry ID
    NCT00674050
    Conditions
    Diabetes Mellitus; Healthy Subjects
    Interventions
    Technosphere Insulin (TI) Inhalation Powder; Albuterol (Salbutamol); Fluticasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-05
    Completion
    2008-10
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus; Healthy Subjects
    InterventionTechnosphere Insulin (TI) Inhalation Powder; Albuterol (Salbutamol); Fluticasone
    PhasePhase 1
    Registry statusCompleted

  • A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis

    NCT00655109 · start 2008-02

    Registered record
    Registry ID
    NCT00655109
    Conditions
    Conjunctivitis, Allergic
    Interventions
    Olopatadine; Fluticasone; Saline; Artificial tears
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-02
    Completion
    2008-03
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConjunctivitis, Allergic
    InterventionOlopatadine; Fluticasone; Saline; Artificial tears
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD

    NCT00535366 · start 2007-10

    Registered record
    Registry ID
    NCT00535366
    Conditions
    Pulmonary Disease, Chronic Obstructive
    Interventions
    Tiotropium; Salmeterol; Fluticasone; Ciclesonide low; Ciclesonide high; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-10
    Completion
    Not recorded
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease, Chronic Obstructive
    InterventionTiotropium; Salmeterol; Fluticasone; Ciclesonide low +2 more
    PhasePhase 2
    Registry statusCompleted

  • Cutivate Lotion HPA Axis Pediatric Study

    NCT00546000 · start 2007-07

    Registered record
    Registry ID
    NCT00546000
    Conditions
    Atopic Dermatitis
    Interventions
    Fluticasone propionate 0.05% lotion
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-07
    Completion
    2008-12
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionFluticasone propionate 0.05% lotion
    PhasePhase 4
    Registry statusCompleted

  • Fluticasone and Salmeterol in Allergic Rhinitis

    NCT01388595 · start 2006-11

    Registered record
    Registry ID
    NCT01388595
    Conditions
    Allergic Rhinitis
    Interventions
    FLUTICASONE PROPRIONATE; Salmeterol; PLACEBO
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-11
    Completion
    2010-10
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis
    InterventionFLUTICASONE PROPRIONATE; Salmeterol; PLACEBO
    PhasePhase 4
    Registry statusCompleted

  • A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS

    NCT00400608 · start 2006-10

    Registered record
    Registry ID
    NCT00400608
    Conditions
    Asthma
    Interventions
    ADVAIR HFA; ADVAIR DISKUS
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-10
    Completion
    2007-02
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionADVAIR HFA; ADVAIR DISKUS
    PhasePhase 4
    Registry statusCompleted

  • New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

    NCT00393952 · start 2006-06

    Registered record
    Registry ID
    NCT00393952
    Conditions
    Asthma
    Interventions
    Fluticasone propionate/Formoterol fumarate 250/10; Placebo; Fluticasone propionate/Formoterol fumarate 100/10; Fluticasone propionate 250; Formoterol fumarate 10
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-06
    Completion
    2008-04
    Enrolment
    557

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionFluticasone propionate/Formoterol fumarate 250/10; Placebo; Fluticasone propionate/Formoterol fumarate 100/10; Fluticasone propionate 250 +1 more
    PhasePhase 3
    Registry statusCompleted

  • Enhancement of in-Vitro GC Function in Patients With COPD

    NCT00241631 · start 2006-04

    Registered record
    Registry ID
    NCT00241631
    Conditions
    COPD
    Interventions
    Fluticasone Propionate; placebo; Theophylline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-04
    Completion
    2007-08
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD
    InterventionFluticasone Propionate; placebo; Theophylline
    PhasePhase 2
    Registry statusCompleted